三阴性乳腺癌的研究和治疗进展

三阴性乳腺癌是将ER、PR和HER2受体均阴性的乳腺癌,具有独特生物学及临床特征的乳腺癌亚型,与基底细胞样乳腺癌有较高的一致性,复发早、进展快、生存短。对于三阴性乳腺癌的治疗,目前并没有推荐的化疗方案,其治疗一般按常规标准治疗进行,而针对三阴性乳腺癌的靶向治疗正在进行临床研究。

Progression for triple-negative breast cancer

Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors（ER/PR）and HER2 protein.It is characterized by its unique molecular profiles,aggressive behaviors,distinct risk factors and patterns of recurrence and metastasis,i～erior prognosis and lack of targeted therapies.And there is a great deal of overlap between triple-negative and basal-like breast cancer.Therapeutic strategies in the setting of this subtype breast cancer remain a challenge.Several clinical trials on anti-EGFR and antiangiogenesis are ongoing.